What Is Wayrilz, and Why Does It Matter? Wayrilz (rilzabrutinib) is a new oral medicine for adults with persistent (lasting 3-12 months) or chronic (lasting more than 12 months) immune ...
Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results